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Abstract In vitro manipulation of membrane sterol level af-
fects the regulation of ion channels and consequently certain
cellular functions; however, a comprehensive study that con-
firms the pathophysiological significance of these results is
missing. The malfunction of 7-dehydrocholesterol (7DHC)
reductase in Smith-Lemli-Opitz syndrome (SLOS) leads to
the elevation of the 7-dehydrocholesterol level in the plasma
membrane. T lymphocytes were isolated from SLOS patients
to assess the effect of the in vivo altered membrane sterol
composition on the operation of the voltage-gated Kv1.3
channel and the ion channel-dependent mitogenic responses.
We found that the kinetic and equilibrium parameters of
Kv1.3 activation changed in SLOS cells. Identical changes
in Kv1.3 operation were observed when control/healthy T
cells were loaded with 7DHC. Removal of the putative sterol
binding sites on Kv1.3 resulted in a phenotype that was not
influenced by the elevation in membrane sterol level.
Functional assays exhibited impaired activation and prolifer-
ation rate of T cells probably partially due to the modified
Kv1.3 operation. We concluded that the altered membrane
sterol composition hindered the operation of Kv1.3 as well
as the ion channel-controlled T cell functions.
Keywords Smith-Lemli-Opitz syndrome . Cholesterol .
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Introduction
Cholesterol (CHOL) is a crucial component of the mammalian
plasma membrane, it determines the biophysical properties of
the lipid bilayer as well as the function of the embedded pro-
teins. CHOL homeostasis of the mammalian cells is strictly
regulated by complex mechanisms [51]. In the last decades,
numerousmalformation syndromes have been associated with
the inborn error of the CHOL synthesis (reviewed in [46]).
The link between reduced CHOL synthesis and a serious
health condition was described first for the Smith-Lemli-
Opitz syndrome (SLOS) [29, 59, 65]. The SLOS phenotypic
spectrum is very broad, ranging from a mild disorder with
behavioral and learning problems to a lethal malformation
syndrome (incidence of SLOS is 1 in 39,000 births [17])
[45, 46]. The disease is characterized by the constellation of
severe birth defects affecting multiple organ systems (central
nervous system, cardiac, pulmonoray, gastrointestinal).
Craniofacial features (microcephaly, a small upturned nose,
ptosis, and micrognathia) and the syndactily of the second
and third toes are the most frequent physical manifestations
of SLOS. Growth failure and feeding problems are also com-
mon in SLOS. Moreover, many SLOS infants have behaviour
problems (autism, hyperactivity, self-injures behavior) [45,
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46]. Irons and his colleagues showed that the SLOS is caused
by the deficiency of 7-dehyrocholesterol-reductase (DHCR7),
which catalyzes the last step in the CHOL biosynthetic path-
way [29]. Altered DHCR7 activity led to increased 7DHC and
reduced CHOL levels both in the serum and in the plasma
membrane of fibroblasts and erythrocytes [16, 61].The sever-
ity of the disease and life expectancy of the patients is mostly
determined by initial serum CHOL level, while the ratio of
7DHC/CHOL has an additional prognostic value [5]. Oral
cholesterol and simvastatin administration are used in the
treatment of SLOS; however, retrospective studies did not
confirm its effectiveness [12, 19, 24, 58].
Ion channels are pore-forming, integral membrane proteins
allowing the transport of inorganic ions down their electro-
chemical gradient across the cell membrane. Voltage-gated
potassium channels (Kv channels) are the largest and most
diverse group of the ion channels including up to 40 members
[23]. They are composed of four, generally identical α-sub-
units, each of which is composed of six transmembrane do-
mains (S1–S6) connected by extracellular and intracellular
loops. S5 and S6 segments with the pore loop between them
form the pore domain (PD) of the channel which includes the
ion conducting pore, whereas S1–S4 and the positively
charged amino acids in S4 make up the voltage-sensing do-
main (VSD). Kv1.3, which belongs to the Shaker subfamily of
Kv channels, is the predominant voltage-gated K+ channel of
human T lymphocytes [18, 39].The main function of Kv1.3
channels during T cell activation is the maintenance of a per-
missive membrane potential (approximately equal to −50mV)
required for appropriate extracellular Ca2+ entry and proper
Ca2+ signaling. By the use of Kv1.3-selective antagonists,
lymphocyte proliferation and IL-2 production can be inhibited
[14, 47]. It has been reported earlier by several labs that
CHOL is a significant regulator of various types of ion chan-
nels including Kv1.3 [27, 49, 52]. Generally, the excess
CHOL content of the plasma membrane suppresses the ion
channel activity by reducing the open probability or conduc-
tivity. These suppressing effects were shown not only for Kv
channels but for Ca2+ and Na+ channels as well [33]. On the
other hand, some of the channels (e.g., TRPV channels and
ENaC [33]) have been referred to as CHOL-dependent,
whereby CHOL depletion reduces the activity of the channels.
We showed earlier that the CHOL loading of T cell membrane
significantly slowed the activation and inactivation kinetics of
Kv1.3 and modified the parameters of the steady-state
activation [27].
It was demonstrated that 7DHC can incorporate into
biomembranes and SLOS patients have an increased 7DHC
level in the plasma membrane [61]. Moreover, accumulation
of the 7DHC in the plasma membrane can affect the physical-
chemical behavior of the lipid bilayer, and also influence the
function of membrane proteins by disrupting/modifying the
raft structure and/or interacting directly with the proteins
themselves [11, 30, 61]. The single-channel conductance of
the BKCa channel, which colocalizes with caveolin in CHOL-
rich membrane domains, is reduced and the voltage depen-
dence of the open probability is right-shifted in SLOS fibro-
blasts [48]. The function of Na+/K+ ATPase is also decreased
in SLOS fibroblast [48].
To our knowledge, there are no other reports, in which the
altered biophysical parameters of a Kv channel and its func-
tional consequences are demonstrated in cells isolated from
SLOS subjects. Here, we demonstrate that the operation of
Kv1.3 channels, which are also expressed in neuronal cells,
is modified in Tcells of SLOS patients as compared to healthy
age-matched control. We have found that changes in the gat-
ing of Kv1.3 channels in SLOS lymphocytes were similar to
those recorded in control T cells loaded with 7DHC using
methyl-β-cyclodextrin/7DHC complex. Removal of the C-
terminal end of Kv1.3 abolished the sterol sensitivity of
Kv1.3, which proves interaction between the channel and
membrane sterols. Furthermore, the modified operation of
Kv1.3 in the SLOS T cells was associated with impaired pro-
liferation rate and a defect in the early steps of Kv1.3- and
Ca2+-dependent activation pathway in CD3+ T cells. We pro-
pose that the ion channel-sterol interaction described in our
study reveals a molecular mechanism that may contribute to
various pathophysiological conditions via influencing the
physiological function of ion channels.
Material and methods
Patients
All eight SLOS patients who were accessible in Hungary (age
7.65 ± 2.23 years) and eight age-matched control patients from
Hungary (age 7.66 ± 1.83 years) were enrolled in the study. On
the basis of clinical severity score, patients were assigned to
three groups: score below 20 means mild disease, while typ-
ical SLOS patients have a score between 20 and 50, and above
50 the severe type of SLOS is manifested [5, 41]. Three of the
patients were characterized with mild disease (age 9
± 1.88 years, serum 7DHC 0.38 ± 0.08 mmol/l, serum CHOL
was 2.64 ± 0.36 mmol/l), and five children with typical disease
(age 7.4 ± 2.13 years, mean serum7DHC and CHOL level was
0.5 ± 0.09 and 1.44 ± 0.26 mmol/l, respectively). After setting
up the diagnosis, all of the enrolled patients received dietary
CHOL substitution [56]. Statin therapy was also started after
diagnosis but in case of two patients it was suspended because
of elevated liver enzymes. Informed consent was obtained
from all individual participants included in the study. Human
blood was obtained following a protocol approved by the
Institutional Review Board of University of Debrecen. All
procedures performed in studies involving human participants
were in accordance with the ethical standards of the
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institutional research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical
standards.
Cells
Five milliliters of heparinized human peripheral venous blood
was drawn from SLOS patients and healthy control children.
Mononuclear cells were separated by Ficoll-Hypaque density
gradient centrifugation. Freshly isolated cells were used for
CFSE assay, and the remaining mononuclear cells were frozen
and stored at −80 °C until patch clamp and CD154 expression
experiments. Following CFSE staining (see below) and acti-
vation, cells were cultured in 24- or 96-well plates at a cell
density of 106 cells/ml in standard RMPI-1640 medium
(Sigma-Aldrich Co., Saint Louis, MO, USA) containing
15 mM HEPES buffer (Sigma-Aldrich Co., Hungary) at
37 °C in humid atmosphere with 5 % CO2. CHO cells
(ATCC, Germany) were cultured in DMEM medium
(Sigma-Aldrich, Hungary), which also contained 10 % FBS,
L-glutamine (2 mM), penicillin (100U/l), and streptomycin
(100 mg/l). Cells were maintained at 37 °C in a humidified
atmosphere of 5 % of CO2 and 95 % air. Cells were passed
every 2–3 days. CHO cells were transduced with retroviral
particles containing mGFP-Kv1.3-WT and mGFP-Kv1.3ΔC
constructs as described in [57].
Analysis of the sterol composition of red blood cells using
GC-MS
Gas chromatography-mass spectrometry (GC-MS) experiments
were carried out by use of the standard protocols. Before ex-
traction ergosterol, as internal standard for sterol quantitation
was added to the homogenates (10 μg/protein mg). Lipids were
extracted according to a modified Folch procedure as described
in [4]. Protein content of cell homogenates was determinedwith
the BCA protein assay kit (Thermo Scientific) using the proto-
col recommended by the manufacturer. Quantitative analysis of
CHOL and 7DHC was carried out by a GC-MS system
(GCMS-QP2010, Shimadzu) equipped with a BPX-1 capillary
column (10m× 0.1mm× 0.1 μm film thickness). An aliquot of
the extracts (corresponding to 50 μg protein) was evaporated,
the residue redissolved in 25 μl benzene followed by addition
of 3 μl N,O-bis(trimethylsilyl)acetamide and kept at room tem-
perature for an hour. A 1-μl aliquot of the resulting
trimethylsilyl ether derivative of the different sterols was
injected onto the column programmed at 30 °C/min from
150 to 290 °C, and maintained isothermally for 3 min.
Identification was made based on CHOL and 7DHC stan-
dard solutions. Quantization was carried out by compari-
son to ergosterol standard.
Electrophysiology
Whole-cell measurements were carried out using Axopatch-
200A/B amplifiers connected to personal computers using
Axon Digidata 1440 digitizers. For data acquisition and anal-
ysis the pClamp10 software package (Molecular Devices,
Sunnyvale, CA) were used. CD4+T lymphocytes were select-
ed for current recording by incubation with mouse anti-human
CD4 antibodies (0.5 μg/106 cells, AMAC, Westbrook),
followed by selective adhesion to petri dishes coated with goat
anti-mouse IgG antibody (Biosource, Camarilo, CA), as de-
scribed previously [39]. Standard whole-cell patch clamp
techniques were used, as described previously [28]. Pipettes
were pulled from GC 150F-15 borosilicate glass capillaries
(Clark Biomedical Instruments, UK) in four stages and fire-
polished to give electrodes of 3–6 MΩ resistance in the bath.
The standard bath solution (S-ECS) was (in mM) 145 NaCl, 5
KCl, 1 MgCl2, 2.5 CaCl2, 5.5 glucose, 10 HEPES (pH 7.35,
305 mOsm). The pipette solution was (in mM) 140 KF, 11
K2EGTA, 1 CaCl2, 2 MgCl2, and10 HEPES (pH 7.20,
∼295 mOsm). To study activation kinetics of Kv1.3, T cells
were depolarized to 50 mV for 15 or 30 ms from a holding
potential −120 mV. Kv1.3 current traces were fitted with a
single exponential function rising to the maximum according
to the Hodgkin-Huxley model (I(t) = Ia × (1 − exp(−t/τa))4 +C,
where Ia is the amplitude of the activating curve component,τa
is the activation time constant of the current, C is the current
amplitude at −120 mV). The activation time constant for a
particular cell was defined as the average of time constants
obtained for at least three depolarizing pulses repeated at ev-
ery 15 s in a sequence. We recorded at least four cells of a
given patient or donor, and the average of the activation time
constants was used to demonstrate the activation kinetics of
control and SLOS groups. To study the inactivation of Kv1.3
channels, 2-s-long step pulses to +40 mV from a holding of
−120 mV were applied to the cells. The fast activation of
outward current is followed by a relatively slow decay of
current corresponding to the C-type inactivation of this chan-
nel. The decaying part of the current traces was fitted with a
single exponential function (I(t) = I0× exp(−t/τin,i) +C, wher I0
is the amplitude of current, τin,i is the inactivation time con-
stant for different groups, and C is the steady-state value of
whole-cell current at the end of the pulse) to attain the time
constant characterizing the inactivation kinetics. The charac-
teristic inactivation time constant for a given cell was deter-
mined as detailed for the activation kinetics. Membrane po-
tential dependence of steady-state activation of the Kv1.3 cur-
rent was determined as follows: cells were held at −120 mV
and depolarized to gradually increasing test potentials. Peak
whole-cell conductance (G(V)) at each test potential was cal-
culated from the peak current (Ipeak) at a test potential V and
the K+ reversal potential (EK) using G(V) = Ipeak / (Vtest − Er).
The G(V) values were normalized for the maximum
Pflugers Arch - Eur J Physiol (2016) 468:1403–1418 1405
conductance (Gnorm) and plotted as a function of test potential
along with the best-fit Boltzmann function (Gnorm = 1/(1 + exp
[−(V − V½) / k], where Gnorm is the normalized conductance, V
is the test potential,V½ is the midpoint, and k is the slope of the
function). We calculated the steady-state parameters at least
four individual cells from each donor. The whole-cell mem-
brane capacitance (C) setting on the amplifier required to can-
cel the transient charging currents evoked by periodic appli-
cation of 5 mV test pulses was considered as the membrane
capacitance of the cells.
7DHC and CHOL loading of T cell membrane
Freshly isolated control (healthy) lymphocytes were washed
twice with Hanks’ solution and suspended in Hanks’ solution
(2 × 106 cells/ml) containing different concentrations of
methyl-β-cyclodextrin/7-DHC (MβCD/7DHC, kind gift of
Lajos Szente, CycloLab Cyclodextrin Research and
Development Laboratory Ltd., Hungary) or methyl-β-cyclo-
dextrin/CHOL (MβCD/C, CycloLab Cyclodextrin Research
and Development Laboratory Ltd., Hungary). In control ex-
periments MβCD/7DHC, MβCD/C was not present in the
solution. Cell suspensions were incubated for 1 h at 37 °C
and washed three times with Hanks’ solution.
CD154 expression detection
Previously isolated control and SLOS mononuclear cells were
stimulated with thapsigargin (1 μM) for 3 h at 37 °C. For flow
cytometry, cells were labeled with phycoerythrin conjugated
mouse anti-CD3 antibody (PE-CD3) and Alexa-488 conjugat-
ed mouse anti-CD154 antibody (A488-CD154) and there
isotype control for 20 min at room temperature according to
the manufacturer’s protocol (Biolegend; San Diego; CA).
After the staining procedure, the fluorescence intensity of T
cells was assessed by BD FacsScan flow cytometer (Beckton-
Dickinson, NJ, USA). In all experiments, at least 10,000
events were recorded and analyzed using FCS Express 4 soft-
ware. Dead cells were excluded by gating based on side and
forward scatter.
CFSE staining and analysis
To study proliferation of lymphocytes, we applied the
modified version of carboxyfluorescein succinimidyl es-
ter (CFSE) dilution essay, originally described by Lyons
et al. [36–38, 43]. The final concentration of CFDA-SE
(CellTrace™ CFSE Cell Proliferation Kit, Life
Technologies Co., Waltham, MA, USA) was 1 μM that
provided a 100- to1000-fold increase in the fluorescence
intensity of the loaded cells compared to the autofluo-
rescence of unstained cells. We applied 500 ng/ml sol-
uble anti-CD3 antibodies combined with 1 μg/ml
soluble mouse anti-human CD28 (Sigma-Aldrich Co.,
Saint Louis, MO, USA) for specific T cell stimulation
in the mononuclear cell cultures. The flow cytometry
analysis was performed on a BD FACScan™ cytometer.
Fluorescence gate settings for lymphocytes are shown
on Fig. 7a, b. Lymphocytes were selected from mixed
cell populations of PBMC by their light scatter profile
on FACS analysis (Fig. 7a). Cell proliferation was de-
termined based on the decreasing CFSE intensity in the
green channel (Fig. 7c). The indicator of proliferation
was the division index (DI), calculated by the following
formula:
DI ¼
Xn
k¼1
Ak
 !. Xn
k¼0
Ak
 !
where k points to the nth generation of cells, and Ak is
the cell number in the kth division cycle according to
Fig. 7c.
Data analysis
Prior to analysis whole-cell current traces were corrected for
ohmic leak. Nonlinear least squares fits were done using the
Levenberg-Marquardt algorithm. Fits were evaluated visually
as well as by the residuals and the sum of squared differences
between the measured and calculated data points. Data are
expressed as mean ± SEM. For pairwise comparisons
Student’s t test or Mann–Whitney rank sum test (nonnormal
distribution population) were applied. For multiple compari-
sons, one-way or two-way ANOVA with post hoc Holm-
Sidak (HS) test were used. Statistical significance was taken
as p < 0.05 (* indicates statistical difference) or p < 0.001
(** indicates statistical difference).
Results
Sterol composition of SLOS membrane
We characterized the sterol profile of the red blood cells
(RBCs) from SLOS patients and age-matched control do-
nors in order to gain information regarding the alteration
of the sterol environment, and especially that of the
7DHC/CHOL ratio in the cell membrane induced by the
SLOS disease [16, 61]. Table 1 shows the elevated 7DHC
and reduced CHOL levels in all of the SLOS samples,
while 7DHC in the control samples was undetectable.
8DHC, which is a common isomer of 7DHC, was also
identified in every SLOS sample (data not shown) [8].
Results of the RBC sterol composition analysis are com-
parable to the comprehensive study by Russo et al. [16].
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Expression level of Kv1.3 channels in SLOS T cells is
similar to that in healthy donors
Since Kv1.3 channel is the main voltage-gated K+ channel of T
lymphocytes and plays pivotal role in regulating of the prolif-
eration of T cells, we examined the expression and biophysical
properties of Kv1.3 channels in SLOS patients. Current density
(CuD: the peak current normalized to membrane capacitance,
proportional to the number of channels per unit area) provides
information about the impact of the channels on the membrane
potential control of the cell, since a given number of channels
regulate the membrane potential more readily in a smaller cell
than in a larger one. T cells were held at −120 mV (holding
potential) and depolarized to +50 mV for 15 ms in whole-cell
configuration to determine whole cell peak currents (Ip), then Ip
of an individual cell was divided by the membrane capacitance
(C) of the particular cell to calculate current density. Whole-cell
peak currents and whole-cell membrane capacitance were the
same in control and SLOS groups, and there was no statistical
significant difference between the current densities of control
and SLOS T cells (see Fig. 1 and Table 2).
Slowing of Kv1.3 current kinetics in SLOS T cells
We previously demonstrated that the increase of CHOL con-
tent of the T cell membrane influenced the gating kinetics of
Table 1 7DHC and CHOL
composition of SLOS and control
red blood cells
Sample Clinical severity type Membrane sterols (nmol/L)
CHOL 7DHC 7DHC/CHOL
SLO#1 M 0.93 0.10 0.11
SLO#2 M 1.23 0.30 0.25
SLO#3 M 1.48 0.11 0.08
SLO#4 T 1.73 0.93 0.54
SLO#5 T 3.44 0.53 0.16
SLO#6 T 0.13 0.76 5.63
SLO#7 T 0.10 0.67 6.47
Mean ± SEM – 1.29 ± 1.14 0.49 ± 0.32 1.89 ± 2.86
Control#1 – 5.08 ND –
Control#2 – 4.75 ND –
Control#3 – 4.36 ND –
Control#4 – 4.83 ND –
Control#5 – 2.46 ND –
Mean ± SEM – 4.3 ± 0.47 – –
RBC red blood cell, CHOL cholesterol, 7DHC 7-dehydrocholesterol, ND not detectable,M mild, T typical
Fig. 1 Expression level of Kv1.3
in SLOS. a The average whole-
cell current (WCC), b whole-cell
capacitance (C), and c current
density (CuD) for the control and
SLOS donors. Error bars
represent SEM
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Kv1.3 [27]. To study whether the altered sterol profile in
SLOS affects the kinetic properties of Kv1.3 current, we re-
corded Kv1.3 whole-cell currents of T lymphocytes isolated
from SLOS patients and control (age-matched healthy) do-
nors. Figure 2a shows normalized current traces evoked in a
control and an SLOS T lymphocyte upon depolarization to
+50 mV. The activation time constant (τa) (see BMaterial and
methods^) was significantly greater for SLOS cells, i.e., the
kinetics of channel opening is slower in SLOS lymphocytes
(Fig. 2a, d and Table 2). Figure 2b illustrates normalized
current traces recorded during 2-s-long step pulses to
+40 mV: the fast rising of the current is followed by a rela-
tively slow decay, which corresponds to the C-type inactiva-
tion of Kv1.3 channels. By fitting a single-exponential func-
tion to the declining part of these curves, we obtained the
inactivation time constants (see BMaterial and methods^),
which did not show significant increase (Fig. 2e and Table 2).
SLOS modifies the membrane potential dependence
of steady-state activation
As the kinetics of the Kv1.3 gating was affected by the in-
creased 7DHC level, we also investigated the equilibrium pa-
rameters of Kv1.3 activation. Figure 2c displaysGnorm-V plots
for an SLOS and a control T cell along with the best-fit
Boltzmann curves (for details, see BMaterial and methods^):
the sigmoid curve of the voltage dependence of steady-state
activation for SLOS patient is rightward shifted as compared
to the control (Fig. 2c). Comparison of the equilibrium acti-
vation parameters showed that the midpoint of the curve (V1/2,
the membrane potential at which 50 % of the channels is open
at steady state) is significantly more positive for SLOS T cells
without a statistically significant change in the slope factor
(Fig. 2f and Table 2).
Modeling 7DCH/CHOL ratio of the SLOSmembrane in T
cell
To verify if 7DHC incorporation into the T cell membrane
affects Kv1.3 function, we created an SLOS-like sterol
environment by modification of the 7DHC content of healthy
T cells with MβCD/7DHC complex in vitro. To validate the
incorporation of 7DHC into the plasma membrane, untreated
and MβCD/7DHC treated PBMCs were subjected to GC-MS
analysis. Figure 3a shows that the amount of 7DHC in the cell
membrane increases gradually with the higher applied con-
centration of MβCD/7DHC (7DHC level normalized to pro-
tein content was 26.1 ± 1.0 μg/mg for 65 μM MβCD/7DHC
and 66.8 ± 11 μg/mg for 195 μM MβCD/7DHC). Parallel to
the increase in MβCD/7DHC, the CHOL content showed
decreasing tendency, which can be due to the CHOL removal
by the empty MβCD, but the change was not significant as
compared to the untreated group (CHOL level normalized to
protein amount was 18.3 ± 3.7 μg/mg for control, 16.2
± 0.2 μg/mg for 65 μM MβCD/7DHC; 13.3 ± 2 μg/mg for
195 μM MβCD/7DHC). These clearly showed that mem-
brane 7DHC and CHOL ratio is similar to those described in
SLOS patients.
Biophysical properties of Kv1.3 in 7DHC-loaded T cells
resemble those observed in SLOS
Next, we characterized the kinetic and equilibrium parameters
of Kv1.3 gating in the 7DHC-loaded CD4+ T cells. First, the
activation kinetics of Kv1.3 channels was measured for
7DHC-loaded cells and we found that activation kinetics be-
came slower as the 7DHC level increased in the membrane
(Fig. 3b, d, Table 3). For the inactivation kinetics, we found
that the time constant increased compared to untreated cells
(Table 3). Finally, the voltage dependence of steady-state ac-
tivation was evaluated for T cells treated with different
amounts of MβCD/7DHC: just as described for SLOS cells,
the midpoint of activation, i.e., the half-maximal voltage was
shifted to the positive voltages (Fig. 3c, e and Table 3) but
slope factor did not change (Fig. 3e, Table 3). These data
together suggest that the change of the membrane 7DHC con-
tent can be responsible for the altered Kv1.3 function in
SLOS. Current density, whole-cell peak current, and mem-
brane capacitance were also determined for 32.5, 65, and
195 μM MβCD/7DHC treatments. Although membrane
Table 2 Parameters of Kv1.3
currents recorded from healthy
subjects and SLOS patients
Kv1.3 current parameter Healthy subject (Control) SLOS patient p value
Peak current (pA) 528.0 ± 69 (n = 56) 497.5 ± 31 (n = 51) 0.7
Membrane capacitance (pF) 2.1 ± 0.1 (n = 56) 2.0 ± 0.2 (n = 51) 0.69
Current density (pA/pF) 282.5 ± 42.9 (n = 56) 309.8 ± 39 (n = 51) 0.65
Activation time constant (ms) 0.59 ± 0.02 (n = 56) 0.75 ± 0.03 (n = 51) 0.001*
Inactivation time constant (ms) 227.8 ± 14.2 (n = 38) 253.7 ± 21.4 (n = 45) 0.327
V1/2 (mV) −26.9 ± 0.9 (n = 41) −22.0 ± 1.9 (n = 35) 0.03*
k (mV) 11.7 ± 0.5 (n = 41) 10.6 ± 0.5 (n = 35) 0.14
V1/2 midpoint of steady-state activation, k slope factor of the steady-state activation
*Statistical difference with p < 0.05
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capacitance did not change, the whole-cell peak currents de-
creased significantly upon the 7DHC loading (Table 3).
Consequently, the MβCD/7DHC loading significantly de-
creased the current density of Kv1.3 of T cells unlike for those
from the SLOS patients (Fig. 3f and Table 3).
Comparison of CHOL and 7DHC loading
In our previous study, we demonstrated that in vitro loading of
CHOL slowed the kinetics and modified the steady-state pa-
rameters of Kv1.3 gating. Similar changes in the biophysical
parameters of Kv1.3 gating were found in the current study in
SLOS and SLOS model system [26]. These results raised the
question whether the effect of 7DHC and CHOL loading are
quantitatively similar or different. Therefore, we treated the T
cells with the same concentration of CHOL and 7DHC and
measured the biophysical properties of Kv1.3. We found that
Kv1.3 is more sensitive to 7DHC than CHOL loading at
32.5 μM: 7DHC significantly increased the activation time
constant and shifted V1/2 toward positive voltages, whereas
CHOL did not (Fig. 4a, d and Table 3). At higher concentra-
tions of MβCD/7DHC and MβCD/CHOL both compounds
Fig. 2 Activation of Kv1.3 channels is modified in SLOS T cells. a To
study the kinetic properties of activation of Kv1.3, T cells were
depolarized to +50 mV from −120 mV for 15 ms. Normalized current
traces evoked in an SLOS and a control T cells are shown with the best-fit
curves using Hodgkin-Huxley n4- modell (see BMaterial and methods^). b
To study the inactivation of the Kv1.3 current T cells were depolarized to
+40 mV for 2 s from a holding potential of −120 mV. The representative
current traces for a control and an SLOS cell are displayed with the best-
fitting single exponential function to the declining phase of the curve (also
detailed in the BMaterial and methods^). c Voltage dependence of
equilibrium activation of the Kv1.3 channels in an SLOS (circle) and a
healthy (triangles) T cell along with the best-fit Boltzmann functions is
illustrated. The normalized conductance test potential relationships
(Gnorm-V plot) were obtained and analyzed as described in the BMaterial
and methods.^ d, e The activation (n = 56, 8 donors for control; n = 44, 8
patients for SLOS) and inactivation (n = 38, 8 donors for control; SLOS:
n = 45, 8 patients) time constants for Kv1.3 currents in SLOS and control
T cells. (mean ± SEM, *statistical difference at p = 0.05). f Parameters of
steady-state activation (slope (k) and midpoint (V1/2)) are shown for the
Kv1.3 channels in SLOS and control T cells (mean ± SEM, control:
n = 41, 8 donors; SLOS: n = 38, 8 patients, *statistical difference at
p = 0.05))
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changed the kinetic and steady-state parameters of Kv1.3 gat-
ing but 195 μM MβCD/7DHC was more effective in chang-
ing V1/2 than equimolar MβCD/CHOL (Fig. 4b, c, e, f and
Table 3). Our results suggest that CHOL and 7DHC influence
channel function in a very similar way, however, due to their
structural difference their capacity to modify the operation of
an ion channel could be distinctive.
Removal of the cytoplasmic C-terminal of Kv1.3: loss
of sensitivity to sterol loading
We tested the effect of CHOL and 7DHC loading on a C-
terminal-deleted Kv1.3 channel (mGFP-Kv1.3ΔC), which
lacks the last 84 amino acid residues at its C-terminal and
consequently lacks the two CARC sequences recently
identified on other ion channels as specific CHOL receptor
sites being responsible for the effect of sterols on ion channels
[20, 34, 49, 52]. If CHOL and 7DHC acts on these proposed
receptor sites then Kv1.3ΔC should be CHOL and 7DHC
insensitive. Previously, we showed that biophysical character-
istics of the mGFP-Kv1.3-WTand mGFP-Kv1.3ΔC are iden-
tical; removal of the C-terminal did not change significantly
the gating properties of Kv1.3 [57]. mGFP-Kv1.3-WT and
mGFP-Kv1.3ΔC expressing CHO cells were loaded using
420 μMCHOL and 7DHC, and ionic currents were measured
in outside-out patch configuration. As expected, 420 μM
CHOL or 7DHC shifted the midpoint of the voltage depen-
dence of steady-state activation and increased the activation
time constant in case of the mGFP-Kv1.3-WT CHO cells
(V1/2,WT: −28.9 ± 1.5 for control and −17.5 ± 1.9 mV for
Fig. 3 7DHC loading mimics
SLOS in T cells. a GC-MS
analysis of CHOL and 7DHC
level in MβCD/7DHC treated (65
and 195 μM) control
lymphocytes (from healthy age-
matched donors). MβCD/CHOL
treatment (140 μM) was applied
as a positive control. b Current
traces of Kv1.3 activation are
shown for 7DHC-loaded cells;
same protocol was applied as in
Fig. 2a. c Normalized
conductance of Kv1.3 current is
plotted as a function of the
membrane-potential (see
BMaterial and methods^ and
Fig 2c) for MβCD/7DHC treated
cells; the fitted Boltzmann curves
are also shown. d, e The
activation time constant and the
parameters of equilibrium
activation are shown (n > 7 for
each treatment). f Current density
(CuD) of 7DHC loaded cells
(mean ± SEM, n > 7); * and **
indicate statistical difference at
p = 0.05 and p = 0.01, respectively
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420 μM CHOL, p < 0.001; −19.3 ± 4.7 mV, p = 0.028 for
420 μM 7DHC; τa,WT: 0.45 ± 0.01 ms for control, 0.76
± 0.02 ms for 420 μM MβCD/CHOL, p = 0.002; 0.69
± 0.06 ms for 420 μM MβCD/7DHC, p = 0.008, Fig. 5a, c.)
On the contrary, mGFP-Kv1.3ΔC channels were insensitive
to both CHOL and 7DHC loading (V1/2,ΔC:−26.7 ± 2.7 mV for
control; V1/2,ΔC:−26.3 ± 2.7 mV for 420 μM MβCD/CHOL,
p > 0.05; V1/2,ΔC: −23.1 ± 1.1 mV for 420 μMMβCD/7DHC,
p > 0.05); and τa,ΔC: 0.59 ± 0.04 ms for control, 0.55 ± 0.02 ms
for 420 μM MβCD/CHOL, p > 0.05; 0.65 ± 0.04 ms for
420 μMMβCD/7DHC, p > 0.05, Fig. 5b, d).
Activation and proliferation of SLOS Tcells is suppressed
We aimed to study the effects of the altered 7DHC/CHOL
ratio on the Kv1.3-dependent biological functions of T cells
such as activation and proliferation. To assess the effect of
SLOS on T cell activation, we measured the expression of
CD154 of lymphocytes. CD154 is a marker of activation on
T lymphocytes stimulated through calcium-triggered NFAT
pathways [1, 6]. We assumed that the modified ion channel
function in SLOS influences the Kv1.3-dependent calcium
signaling during T cell activation, which could change the
expression of CD154. Mononuclear cells were stimulated
with thapsigargin to trigger the calcium-dependent activation
pathway and labeled with PE-conjugated anti-CD3 and A488-
conjugated anti-CD154 antibody. T cells were identified by
gating on CD3+ cells (Fig. 6a, b). Our results indicate that
the ratio of CD154+ T cells decreased significantly in SLOS
compared to the age-matched healthy controls (fraction of
CD154+CD3+cells in SLOS: 8.6 ± 3.2 %, control: 21.1
± 2.8 %, Fig. 6c, d, p < 0.001). The mean fluorescence inten-
sity (MFI) of SLOS lymphocytes was also reduced, but the
difference was not significant (MFI of CD154 in SLOS 15.5
± 2.1 a.u.; in control group 20.4 ± 3.7 a.u., p = 0.13). We also
tested the proliferation capacity of T cells using the CFSE
staining technique, which is a suitable method to observe the
proliferation characteristics of lymphocytes with flow cytom-
etry (Fig. 7a, b).We found that the 5-day antiCD3/antiCD28
stimulation (see details in BMaterial and methods^) of T lym-
phocytes was less effective in SLOS than in the control group
(Fig. 7c, d). The division indices of T lymphocytes were 29.4
± 3.5 and 61.1 ± 7.1 % for SLOS and the control group,
respectively (p = 0.002, Fig. 7e).
Discussion
In the present study, we reported for the first time that
accumulation of 7DHC in the cell membrane modifies
the operation of the voltage-gated ion channel Kv1.3 both
in SLOS T cells and in T cells acutely loaded with 7DHC
(MβCD/7DHC-treated lymphocytes), and also influencesTa
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the Ca2+-dependent signaling events coupled to Kv1.3
activity. We showed that (1) elevated membrane 7DHC
level in SLOS T cells modifies the equilibrium and kinetic
properties of Kv1.3 activation, (2) MβCD/7DHC loading
of T cell membrane, which mimics the sterol environment
in SLOS, results in similar changes in Kv1.3 gating as
described in SLOS, (3) the Kv1.3 construct (Kv1.3ΔC)
lacking the putative sterol-binding sequences on the C-
terminus is insensitive to the sterol-modification of the
membrane, and (4) the early steps of the Ca2+-dependent
T cell activation pathway as well as the division index of
SLOS T cells is hampered. These data all support that
presence of 7DHC in the plasma membrane affects
Kv1.3 function and the cellular processes which depend
on Kv1.3 activity.
The laboratory medicine profile (i.e., serum sterols) of
SLOS patients is quite diverse, a wide range of plasma
7DHC and CHOL concentrations were reported even for ge-
netically homogenous patient groups [16, 42]. Furthermore,
the 7DHC/CHOL ratios in the plasma and in red blood cells
also show significant variations among patients. Therefore,
we aimed at confirming that cellular 7DHC to CHOL ratios
display 7DHC accumulation in our patient group. In the ab-
sence of sufficient amount of blood samples for the character-
ization of the sterol composition of the T cell membrane, we
monitored the 7DHC content as well as the ratio of
CHOL/7DHC in RBCs isolated from SLOS patients
(Table 1). Our data confirmed a decrease in CHOL and in-
crease in 7DHC levels in the RBCs of every donor (see
Table 1) as compared to healthy counterparts. Moreover,
Fig. 4 Kv1.3 sensitivity to
7DHC- and CHOL-loading is
different. Control lymphocytes
(from healthy age-matched
donors) were loaded with 7DHC
and CHOL at equal
concentrations, and activation
kinetics and voltage dependence
of steady-state activation were
investigated as detailed in
Fig. 2a, c. a–c Average activation
time constants of Kv1.3 current at
32.5, 65, and 195 μM
MβCD/7DHC and
MβCD/CHOL concentrations.
d–f Average of the half-maximal
voltage for equilibrium activation
at treatment with 32.5, 65, and
195 μMMβCD/7DHC and
MβCD/CHOL. Data are
presented as mean ± SEM. * and
** represent significant difference
at p = 0.05 and p = 0.001,
respectively
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Fig. 5 Kv1.3 C-terminus is
involved in the sterol mediated
regulation. CHO cells stably
expressing mGFP-Kv1.3-WTand
mGFP-Kv1.3ΔC channels were
loaded with 7DHC and CHOL
(both at 420 μM), and activation
kinetics and voltage dependence
of steady-state activation were
studied as detailed before in
Fig. 2a, c. a, b Average activation
time constants for mGFP-KV1.3-
WT (a) and mGFP-Kv1.3ΔC (b)
current upon MβCD/CHOL and
MβCD/7DHC treatment. c, d
Average half-maximal voltage for
steady-state activation of
mGFP-Kv1.3-WT (c) and
mGFP-Kv1.3ΔC (d) channels
upon CHOL and 7DHC loading.
Bar graphs show mean ± SEM
for n > 5. * and ** represent
significant difference at p = 0.05
and p = 0.001, respectively
Fig. 6 CD154 expression in
SLOS is hampered. a, b
Representative dot-plots of flow
cytometric measurement for
healthy (control) (a) and SLOS
(b) PBMCs labeled with anti
CD3-PE and anti-CD154-
Alexa488 after a 3-h activation
with thapsigargin (1 μM). c
CD154 expression distribution of
CD3+ T cells of a healthy and an
SLOS donor upon thapsigargin
activation (isotype control is also
shown). dMean percentage of
CD154+CD3+ T cells in SLOS
(n = 5) and healthy (n = 4) group
(mean ± SEM is displayed,
*significant difference for
p = 0.05)
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manipulation of the sterol level of T cell membranes with
MβCD/7DHC complex clearly indicated an elevation of
7DHC level, while the CHOL content reduced mildly
(Fig. 3a). We are aware that 7DHC enrichment of the T cell
membrane using MβCD and the consequent altered ratio of
7DHC/CHOL only partly mimics the SLOS plasma mem-
brane. For example, other species of CHOL precursors and
7DHC-derived oxysterols were not present in the T cells treat-
ed with MβCD complexed to CHOL or 7DHC whereas these
compounds are identified in SLOS cells [7, 8, 66, 67].
Nevertheless, 7DHC is the prominent sterol in the SLOS
membrane and the biophysical parameters of Kv1.3 gating
were similarly affected in SLOS and in T cells treated with
MβCD/7DHC complex. This suggests that acute loading of T
cells with 7DHC mimics adequately the effect of the lipid
milieu existing in SLOS on the operation of Kv1.3 [11, 29,
30, 54, 68].
We showed clearly that the voltage dependence of steady-
state activation of Kv1.3 is shifted to more depolarized poten-
tials in SLOS T cells as compared to age-matched control T
cells. However, the shift in the V1/2 is relatively small in SLOS
T cells as compared to T cells treated with MβCD/7DHC.
This could be explained by the heterogeneity of the patient
group regarding 7DHC levels, 7DHC/CHOL ratio or the
Fig. 7 Proliferation of T cells in
SLOS is impaired (a, b). Dot-
plots show the gating procedure
for lymphocytes based on their
light-scatter properties (SSC vs.
FSC). a The stimulated control
PBMC population on day 0, and
b the stimulated population on
day 5 following activation:
activated T cells have higher light
scatter intensities andmainly dead
cells are outside the gate. c, d
CFSE fluorescence intensity
histograms obtained for a healthy
donor (c) and a representative
SLOS sample (d). A marker was
placed over the divided (D) and to
the undivided cell (U.D.)
subpopulations. e The ratio of
divided cells and all gated cells is
shown for SLOS (n = 4) and
control (n = 4) group (data is
represented as mean ± SEM,
**p = 0.007)
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severity of the disease. Nevertheless, the very clear and mono-
tonic dose dependence of the activation time constant and the
V1/2 on the MβCD/7DHC concentration (Fig. 3) suggests that
the gating parameters of Kv1.3 are qualitatively and quantita-
tively related to 7DHC loading of the cells. Here, we would
also note that we could not identify a correlation between the
7DHC level (or 7DHC/CHOL ratio) and the extent of the
change in Kv1.3 biophysical parameters in SLOS T cells.
This latter may be explained by the low number of donors
included in this study.
Our experiments also addressed an obvious question: how
does the altered membrane sterol composition impair the gat-
ing of Kv1.3 in SLOS? According to the current theories
sterols and ion channels can interact directly or membrane
sterols can affect the operation of ion channels by influencing
the biophysical properties of the cell membrane (membrane
fluidity, membrane compartmentalization) [11, 20, 34]. Strong
pieces of evidence support both theories and these two models
are not mutually exclusive. The effect of 7DHC on the bio-
physical properties of the cell membrane is contradictory. For
example, it has been demonstrated that 7DHC destabilizes
cholesterol rich domains, increases the membrane fluidity
and alters the protein pattern of rafts [11, 30, 61]. On the
contrary, according to Liu et al., the difference between
CHOL and 7DHC from the perspective of membrane ordering
and condensation is essentially imperceptible [35]. All in all,
we cannot exclude the possibility of the indirect regulatory
effect of 7DHC on Kv1.3 gating.
On the other hand, CHOL is a prominent component of the
annular lipid belt around the transmembrane segment of ion
channels thereby stabilizing the conformation of the channel
[33]. It seems that VSDs and not the pore domain of Kv
channels require the lipid belt [50]. Recent structure function
studies show that the VSDs of Kv1.2 are positioned at the
corners of the square-shaped PD creating deep grooves be-
tween the adjacent subunits. These grooves are expected to
be filled with lipids whose ordering may be different than the
rest of the membrane, generating optimal environment for
specific lipid-protein interactions [60]. In SLOS, 7DHC sub-
stitutes CHOL in the cell membrane and may impair direct
CHOL-protein interactions of annular lipids which may result
in altered operation of the VSD’s.
As for the specific CHOL-ion channel interaction, several
CHOL binding motifs of the membrane and intracellular pro-
teins have been described in the literature recently (CRAC,
CARC, and CCM motif), which serve as specific CHOL re-
ceptor sites [20, 34]. Due to the low stringency requirements
for the amino acid pattern of these motifs should be accepted
with careful skepticism but it is notable that a simple point
mutation or deletion of these selected motifs could totally
abolish CHOL sensitivity of ion channels [44, 49, 52].
Based on the work of Dopico et al., we identified several
CARC and CRAC motifs randomly distributed along the
amino acid sequence of Kv1.3 (including N-terminal, trans-
membrane segments and the C-terminus of the channel) [52].
Some of them overlappedwith highly conservative residues of
Kv channels such as the voltage sensor or the activation gate,
others were located on the variable regions of the Kv1.3.
Mutational analysis of the conservative regions would be
problematic since it has been demonstrated that simple point
mutations of identical parts of Shaker channel can cause non-
conducting channels [25, 32]. On the contrary, relatively large
perturbations in the distal C-terminus of the channel are well
tolerated without a significant effect on the gating of Kv1.3
[57]. Therefore, we decided to study a mutant Kv1.3 which
lacks the putative cholesterol motifs of the distal C-terminal.
Surprisingly, truncation of the distal C-terminus resulted in a
phenotype that was resistant to the manipulation of CHOL and
7DHC content of the membrane (Fig. 5). We propose that
CARC motifs of the C-terminal interact with membrane cho-
lesterol of the inner leaflet via their hydrophobic residues and
mediate sterol sensitivity of Kv1.3. A similar conclusion was
reached by Robinson et al. who envisioned that the C-terminal
of the P2X7 ion channel dips back into the plasma membrane
and contacts the membrane via palmitoyl groups and hydro-
phobic residues [49]. Further experiments including mutagen-
ic scanning analysis of the putative C-terminal cholesterol
recognition sites are necessary to reveal the exact identity/
function of the CARC/CRAC domains of Kv1.3. It is also
notable, that other members of the Kv family have distinct
amino acid residues fromKv1.3 at equivalent positions, which
do not fulfill the requirement of the CRAC or CARC pattern
and thus, their sensitivity to sterols might be different.
Furthermore, 7DHC, at identical loading concentrations, is
more effective in changing the biophysical parameters of
Kv1.3 gating than CHOL (Fig. 4). This may imply that the
affinity of the sterol binding motif of Kv1.3 is different for
CHOL and 7DHC and/or the bound sterols affect ion channel
function differently (e.g., affecting the coupling between the
VSD and the PD through the activation gate of the channel
which is located close to the sterol binding domains).
SLOS T cells had the same current density as the age-
matched control whereas Bacute^ in vitro 7DHC elevation in
the membrane decreased the current density, which can be
accounted for by the suppression of the Kv1.3 current
(Figs. 1c and 3f). We think this discrepancy can be explained
with the Bexposure time^ to 7DHC treatment: under in vivo
circumstances, the cells can build up compensatory mecha-
nisms resulting in the same whole-cell potassium conductance
as for the control, while in vitro elevation of 7DHC level with
its 60-min duration is not sufficient, e.g., to recruit new Kv1.3
channels into the plasma membrane. We found a similar phe-
nomenon in our former study, where acute cholesterol treat-
ment decreased the current density of Kv1.3, whereas
hypercholesterinaemic T cells had the same current density
as the age-matched control [53]. Currently, we do not know
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either the nature of the reduction in the K+ conductance upon
acute exposure of the cells to sterols or the origin of the puta-
tive compensatory mechanism. The suppression of the current
may originate from a change in any one or a combination of
three possible factors due to increased 7DHC/CHOL ratio:
single channel current could decrease and/or open probability
could decrease and/or number of channels could decrease
[13, 15, 52].
Several studies reported that the modification of the oper-
ation of ion channels due to inherited mutations, which is
often hallmarked by the change in the equilibrium and kinetic
parameters of activation (or inactivation), leads to diseases
such as epilepsy (Kv1.2), episodic ataxia (Kv1.1), and long
QT-syndrome (Kv7.1 or KCNQ1) [1, 2, 55]. We obtained
similar changes in the biophysical parameters of Kv1.3 gating
(slower activation kinetics and shift in the voltage dependence
of steady-state activation toward positive potentials) in SLOS
Tcells as in channelopathies listed above. This rightward shift
in the voltage dependence of steady-state activation can have
pathophysiological consequences similar to the loss-of-
function mutations. The more positive half-maximal voltage
in SLOS Tcells can lead to reduced activity of Kv1.3 channels
under physiological conditions, which should appear in the
cellular functions coupled to the activity of Kv1.3. Kv1.3 is
a crucial voltage-gated ion channel of lymphocytes, and its
main function is the membrane potential control of T cells,
thereby providing constant driving force required for Ca2+
entry during T cell activation. Consequently, suppression of
the function of Kv1.3 leads to impaired activation and prolif-
eration [10]. Our data is consistent with this: upregulation of
CD154 expression (an early, Ca2+-signal dependent marker of
T cell activation) upon activation of SLOS CD3+ T lympho-
cytes showed a significant reduction as compared to healthy
donors [6, 62]. Also, the Blong-term effect^ of modified oper-
ation of ion channels could be traced with the proliferation
assay: SLOS cells tended to divide at a lower rate compared
to control T cells, a phenomenon which was clearly shown for
Kv1.3 inhibitors [10, 63]. The Ca2+-signaling-linked activa-
tion of T lymphocytes is a classic example of the interplay of
ion channels, transporters, and signaling molecules (see
above), reviewed in [22, 64]. Even though the sterol sensitiv-
ity of Kv1.3 is a potential mechanism for the reduced T cell
activation/proliferation, we cannot exclude that the altered lip-
id milieu in SLOS affects other transporters and/or signaling
molecules, which contribute to the altered T cell function in
SLOS. Also, we should not exclude the significance of the
toxic effects of 7DHC and oxysterols (including 7DHC-
derived oxysterols), which were shown earlier to hinder acti-
vation and/or proliferation of cells and cause retinal degener-
ation in a rat model of SLOS [21, 40, 68]. It has been demon-
strated that SLOS-derived fibroblasts show impaired Na/K
pump function, increased Ca2+ permeability, and reduced pro-
liferation [61]. These data confirm our hypothesis that altered
function of various ion transporters, such as the hereby studied
Kv1.3, can have functional consequences on the immune re-
sponses in SLOS. In mouse models of SLOS (7DHR−/− an-
imals), it was recently reported that mast cells showed consti-
tutive cytokine production and hyper-degranulation upon IgE
receptor activation, which occurred due to the altered raft sys-
tem of SLOS cell membrane [31]. Even though immunodefi-
ciency was not recognized initially as a part of SLOS, two
recent case reports described serious infections in these pa-
tients. They proposed immunodeficiency behind this phenom-
enon, which is consistent with the data regarding altered Tcell
activation/proliferation [3, 9].
In summary, we showed that changes in the biophysical
properties of Kv1.3 channels in SLOS are due to the altered
7DHC/CHOL ratio, and the sterol–channel interaction is con-
veyed by sterol binding motifs on the channel. Furthermore,
the modified operation of Kv1.3 influences the linked cellular/
signaling processes, which can lead to the dysfunction of the
cells. We also conclude that C-terminus of Kv1.3 is highly
involved in the sterol-mediated regulation of the channel.
Significance of the two putative CHOL binding sites not clear
yet, but this experiment implies their role in the regulation of
Kv1.3.
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